When ENT says they can't secure an airway, hospice is the only answer. And a palliative trach will result in less morbidity than the emergent one they'd have to do at 3am on a Sunday when the airway goes to s***. Because it never happens at 11am on a Tuesday.As an anaesthesiologist/intensivist I have no oncological input into this fascinating and impressive thread (hats off to your breadth of knowledge), but that has to be the most brain dead airway plan I’ve ever heard of.
I have seen airway centered lesions temporarily swell after immunotherapy administration more than once so you either secure the airway early or not at all. The path suggested by ENT is a recipe for a horrible middle of the night death due to an airway that can’t be secured.
-
CycleTrack and SDN are teaming up to make medical school admissions more transparent and accessible! Read the announcement to learn how we’re supporting the future of CycleTrack’s free application-tracking tools .
- Home
- Forums
- Physician and Resident Communities (MD / DO)
- Internal Medicine and IM Subspecialties
- Hematology / Oncology
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
clinical cases
Started by redeyelopez
Get help with your application
Use all the free resources available to you from SDN: articles, guides, expert advising, forums discussions, and school research.
Have a really strange/tough sarcoma case.
31 year old.
Right leg periosteal sarcoma, low grade, MDM2+, resected years ago. No chemo or RT given.
Now, 4 years since his surgery, had a left lung mass that takes up nearly 80% of the hemithorax -- biopsy shows MDM2+ sarcoma consistent with a periosteal sarcoma. I spoke with pathology who think it remains low-grade -- the biopsy specimen shows no high grade features, but again, it may have been sampled at a non-representative spot.
Surgery does not think they can resect it.
Rad onc does not think it is radiosensitive.
So here's my dilemma: I have an ostensibly low-grade periosteal sarcoma in the lung that takes up 80% of the hemithorax that cannot be resected or radiated. Also, low-grade periosteal sarcomas are apparently not chemosensitive.
What do I do? Assume it's high-grade and give MAP? Accept it's low-grade and give MAP anyways because I have no other options? NGS is pending.
If it's metastatic, isn't that the tell that it's not "low-grade" anymore and appropriate for MAP? I am leaning towards that.
31 year old.
Right leg periosteal sarcoma, low grade, MDM2+, resected years ago. No chemo or RT given.
Now, 4 years since his surgery, had a left lung mass that takes up nearly 80% of the hemithorax -- biopsy shows MDM2+ sarcoma consistent with a periosteal sarcoma. I spoke with pathology who think it remains low-grade -- the biopsy specimen shows no high grade features, but again, it may have been sampled at a non-representative spot.
Surgery does not think they can resect it.
Rad onc does not think it is radiosensitive.
So here's my dilemma: I have an ostensibly low-grade periosteal sarcoma in the lung that takes up 80% of the hemithorax that cannot be resected or radiated. Also, low-grade periosteal sarcomas are apparently not chemosensitive.
What do I do? Assume it's high-grade and give MAP? Accept it's low-grade and give MAP anyways because I have no other options? NGS is pending.
If it's metastatic, isn't that the tell that it's not "low-grade" anymore and appropriate for MAP? I am leaning towards that.
Last edited:
31yo with recurrent sarcoma in 80% of their lung? Are you in the ivory tower and if not how far away is the closest one?
Hah - you read my mind. I am not in academics but have already started referral to the most ivory of towers.31yo with recurrent sarcoma in 80% of their lung? Are you in the ivory tower and if not how far away is the closest one?
My instinct is to honestly delay treatment and let an expert center manage it, but I need to make sure they can actually get there in a reasonable time frame. I'm mostly thinking of MAP as a temporizing measure.
Last edited:
I trained in a sarcoma center and I don't touch this s*** ever. Ship it. Today.Hah - you read my mind. I am not in academics but have already started referral to the most ivory of towers.
My instinct is to honestly delay treatment and let an expert center manage it, but I need to make sure they can actually get there in a reasonable time frame. I'm mostly thinking of MAP as a temporizing measure.
Medonc_fellow
New Member
Hey all.
Was consulted on a 52 yo woman with a recent diagnosis of a stage IVB anaplastic thyroid carcinoma.
She's an ECOG 0 and has no relevant comorbidities, with a recent normal TTE.
She underwent surgery on the 12.09.26, achieving an R1 resection.
She's still hospitalized and continues to have postsurgical dysphagia.
We'd like to start CRT as soon as she's cleared by surgery, I'm just wondering about your preferred concurrent chemo regimen.
I see the ATA guidelines list weekly taxol-carbo, taxotere-doxorrubicin, taxol monotherapy, and taxotere monotherapy as options.
I wanted to ask around and get your input based on your experience.
do you have a preferred radiosensitizing regimen in this setting?
thanks!
Was consulted on a 52 yo woman with a recent diagnosis of a stage IVB anaplastic thyroid carcinoma.
She's an ECOG 0 and has no relevant comorbidities, with a recent normal TTE.
She underwent surgery on the 12.09.26, achieving an R1 resection.
She's still hospitalized and continues to have postsurgical dysphagia.
We'd like to start CRT as soon as she's cleared by surgery, I'm just wondering about your preferred concurrent chemo regimen.
I see the ATA guidelines list weekly taxol-carbo, taxotere-doxorrubicin, taxol monotherapy, and taxotere monotherapy as options.
I wanted to ask around and get your input based on your experience.
do you have a preferred radiosensitizing regimen in this setting?
thanks!
Stage IV right-sided colon, pMMR, KRAS mutant, HER2 0.
Progressed on FOLFOX and FOLFIRI with avastin. Widespread liver mets.
Bilirubin 4.5 without any targets for biliary stenting on MRCP. Widespread liver disease.
Has anyone given regorafenib, lonsurf, or fruquitinib with bili 4.5? FDA label and everything I am reading is saying that's a no-go.
Progressed on FOLFOX and FOLFIRI with avastin. Widespread liver mets.
Bilirubin 4.5 without any targets for biliary stenting on MRCP. Widespread liver disease.
Has anyone given regorafenib, lonsurf, or fruquitinib with bili 4.5? FDA label and everything I am reading is saying that's a no-go.
I would not. It's only going to get worse from here unfortunately.Stage IV right-sided colon, pMMR, KRAS mutant, HER2 0.
Progressed on FOLFOX and FOLFIRI with avastin. Widespread liver mets.
Bilirubin 4.5 without any targets for biliary stenting on MRCP. Widespread liver disease.
Has anyone given regorafenib, lonsurf, or fruquitinib with bili 4.5? FDA label and everything I am reading is saying that's a no-go.
Not a case I need help with...just...WTAF.
67M, history...b/l breast cancer (2008 and 2012), Stage II HNSCC (2021), lung adeno metastatic to adrenal s/p resection (2022), papillary thyroid cancer (2023) and now bladder cancer. Germline genetics negative. HNSCC, lung and bladder all molecularly distinct.
Wife has a history of breast cancer and thyroid cancer too. They live in an off-grid property out in the woods. I suspect their well water is actually just straight benzene.
67M, history...b/l breast cancer (2008 and 2012), Stage II HNSCC (2021), lung adeno metastatic to adrenal s/p resection (2022), papillary thyroid cancer (2023) and now bladder cancer. Germline genetics negative. HNSCC, lung and bladder all molecularly distinct.
Wife has a history of breast cancer and thyroid cancer too. They live in an off-grid property out in the woods. I suspect their well water is actually just straight benzene.
Medonc_fellow
New Member
I have two similar cases where conflicting imaging findings significantly upstage localized breast cancer and would appreciate your input as to how you would assign a clinical stage:
Case 1.
69 yo woman with left breast grade 2 IDC detected on screening mammography while undergoing surveillance for follicular lymphoma.
— Mamography reports 9 mm spiculated nodule.
— Contrast mammography describes it's associated with segmental enhancement.
— USG measures the nodule at 13 mm, with 2 associated hypoechoic nodules (8 mm and 4 mm).
— 2 cm by palpation.
I talked to breast imaging, they said that the "main" mass is 13 mm and the mass + area of segmental enhancement = 56 mm. I asked if the area of enhancement could be in situ, they said sure, but it's possible for it to have invasive carcinoma as well.
Especially worried bc going from a T1c → T3 would mean she is high clinical risk and would need a genomic signature to forgo ChT, which she can't afford. It'd also mean she would have to undergo SLNB. She's already received 244 mg/m2 of Adriamycin during her R-CHOP.
Case 2.
54 yo woman with left breast IDC detected on screening mammography as well.
— Mamography reports multifocal disease (17 mm and 11 mm).
— Contrast mammography reports non mass segmental enhancement with pleomorphic linear calcifications measuring 7 cm overall.
— Couldn't really identify the tumor by palpation, just an area of increased density but not a tumor per se.
I feel like management wouldn't really change in this case, I'd offer neoadjuvant THP regardless. I would stage w/ PET if T3 N0, but wouldn't do a PET if T1c N0. Would you just stage and move on?
Those calcifications and area of enhancement sound like in situ to me, path didn't report an in situ component though. It feels like she will end up undergoing mastectomy either way in order to remove both the mass + area of enhancment.
Case 1.
69 yo woman with left breast grade 2 IDC detected on screening mammography while undergoing surveillance for follicular lymphoma.
— Mamography reports 9 mm spiculated nodule.
— Contrast mammography describes it's associated with segmental enhancement.
— USG measures the nodule at 13 mm, with 2 associated hypoechoic nodules (8 mm and 4 mm).
— 2 cm by palpation.
I talked to breast imaging, they said that the "main" mass is 13 mm and the mass + area of segmental enhancement = 56 mm. I asked if the area of enhancement could be in situ, they said sure, but it's possible for it to have invasive carcinoma as well.
Especially worried bc going from a T1c → T3 would mean she is high clinical risk and would need a genomic signature to forgo ChT, which she can't afford. It'd also mean she would have to undergo SLNB. She's already received 244 mg/m2 of Adriamycin during her R-CHOP.
Case 2.
54 yo woman with left breast IDC detected on screening mammography as well.
— Mamography reports multifocal disease (17 mm and 11 mm).
— Contrast mammography reports non mass segmental enhancement with pleomorphic linear calcifications measuring 7 cm overall.
— Couldn't really identify the tumor by palpation, just an area of increased density but not a tumor per se.
I feel like management wouldn't really change in this case, I'd offer neoadjuvant THP regardless. I would stage w/ PET if T3 N0, but wouldn't do a PET if T1c N0. Would you just stage and move on?
Those calcifications and area of enhancement sound like in situ to me, path didn't report an in situ component though. It feels like she will end up undergoing mastectomy either way in order to remove both the mass + area of enhancment.
I'm a huge fan of neoadjuvant treatment. But for case 1, barring an MRI and genomic risk stratification as options, I'd go to surgery first and figure it out on the back end. FWIW, for a Grade 2, without +LN, I'd just use TC if I was going to use chemo anyway, so no anthracycline concerns there.
For case 2, I'd just get CT and bone scan, use neoadjuvant THP and see how things went.
For case 2, I'd just get CT and bone scan, use neoadjuvant THP and see how things went.
1. I agree with breast MRI here. I also agree that if lymph nodes are negative but she warrants chemotherapy that I would do TC.
2. For case 2, I have liked the approach of starting with THP and pivoting to TDxd+pertuzumab after 4 cycles if you haven’t gotten a CR. Technically it’s the opposite way from how they did it in DB 11 but it’s the same therapy. However if you can’t palpate the mass, then I would probably stick to THP followed by surgery and then tailor your adjuvant regimen.
2. For case 2, I have liked the approach of starting with THP and pivoting to TDxd+pertuzumab after 4 cycles if you haven’t gotten a CR. Technically it’s the opposite way from how they did it in DB 11 but it’s the same therapy. However if you can’t palpate the mass, then I would probably stick to THP followed by surgery and then tailor your adjuvant regimen.